Schizophrenia 9

Common Name(s)

Schizophrenia 9

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Schizophrenia 9" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Schizophrenia 9" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Schizophrenia 9" returned 15 free, full-text research articles on human participants. First 3 results:

A normal genetic variation modulates synaptic MMP-9 protein levels and the severity of schizophrenia symptoms.
 

Author(s): Katarzyna Lepeta, Katarzyna J Purzycka, Katarzyna Pachulska-Wieczorek, Marina Mitjans, Martin Begemann, Behnam Vafadari, Krystian Bijata, Ryszard W Adamiak, Hannelore Ehrenreich, Magdalena Dziembowska, Leszek Kaczmarek

Journal: EMBO Mol Med. 2017 08;9(8):1100-1116.

 

Matrix metalloproteinase 9 (MMP-9) has recently emerged as a molecule that contributes to pathological synaptic plasticity in schizophrenia, but explanation of the underlying mechanisms has been missing. In the present study, we performed a phenotype-based genetic association study ...

Last Updated: 31 Dec 1969

Go To URL
Dysregulation of miRNA-9 in a Subset of Schizophrenia Patient-Derived Neural Progenitor Cells.
 

Author(s): Aaron Topol, Shijia Zhu, Brigham J Hartley, Jane English, Mads E Hauberg, Ngoc Tran, Chelsea Ann Rittenhouse, Anthony Simone, Douglas M Ruderfer, Jessica Johnson, Ben Readhead, Yoav Hadas, Peter A Gochman, Ying-Chih Wang, Hardik Shah, Gerard Cagney, Judith Rapoport, Fred H Gage, Joel T Dudley, Pamela Sklar, Manuel Mattheisen, David Cotter, Gang Fang, Kristen J Brennand

Journal: Cell Rep. 2016 05;15(5):1024-1036.

 

Converging evidence indicates that microRNAs (miRNAs) may contribute to disease risk for schizophrenia (SZ). We show that microRNA-9 (miR-9) is abundantly expressed in control neural progenitor cells (NPCs) but also significantly downregulated in a subset of SZ NPCs. We observed a ...

Last Updated: 31 Dec 1969

Go To URL
Regulators of G-protein signaling 9 genetic variations in Chinese subjects with schizophrenia.
 

Author(s): Y S Zhu, Y X Li, X M Qiao, H B Zhang

Journal:

 

To identify single-nucleotide polymorphisms that contribute to the genetic susceptibility to schizophrenia, we examined the potential association between schizophrenia and 9 single nucleotide polymorphisms (rs1530351, rs4791230, rs2869577, rs8077696, rs8070231, rs2292592, rs9916525, ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Schizophrenia 9" returned 1 free, full-text review articles on human participants. First 3 results:

Matrix Metalloproteinase-9 as a Novel Player in Synaptic Plasticity and Schizophrenia.
 

Author(s): Katarzyna Lepeta, Leszek Kaczmarek

Journal: Schizophr Bull. 2015 Sep;41(5):1003-9.

 

Recent findings implicate alterations in glutamate signaling, leading to aberrant synaptic plasticity, in schizophrenia. Matrix metalloproteinase-9 (MMP-9) has been shown to regulate glutamate receptors, be regulated by glutamate at excitatory synapses, and modulate physiological ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

There are currently no open clinical trials for this condition.